Video

Urology Times 50 Innovations Series: Dr. Kelvin Moses on sipuleucel-T for mCRPC

Author(s):

Urology Times staff

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are high-lighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Kelvin A. Moses, MD, PhD, discusses the prostate cancer treatment sipuleucel-T (Provenge). Moses is an associate professor of urology and fellowship director of urologic oncology at Vanderbilt University Medical Center, Nashville, Tennessee.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Ruben Olivares, MD, answers a question during a Zoom video interview
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
1 expert in this video
1 expert in this video
Related Content
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
June 20th 2025

FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

Hannah Clarke
The phase 1 study is set to begin later this year.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
Real-world studies compare overall survival between ARPIs in mCSPC
June 19th 2025

Real-world studies compare overall survival between ARPIs in mCSPC

Mehmet Asim Bilen, MD Hannah Clarke
"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke
ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
June 17th 2025

FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

Hannah Clarke
Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
© 2025 MJH Life Sciences

All rights reserved.